These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 33092689)

  • 61. Letter to the editor on "Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial" by Udwadia et al.
    Medisetty MK; Patel A; Pujari S
    Int J Infect Dis; 2021 Apr; 105():722. PubMed ID: 33601033
    [No Abstract]   [Full Text] [Related]  

  • 62. Letter in response to the article: Pros and cons for use of statins in 59 people with coronavirus disease-19 (COVID-19)(Ray, S et al.).
    Zhao T; Peng L
    Diabetes Metab Syndr; 2021; 15(1):21. PubMed ID: 33279832
    [No Abstract]   [Full Text] [Related]  

  • 63. Letter to the Editor - in response to: Cardiac injury prediction and lymphocyte immunity and inflammation analysis in hospitalized patients with coronavirus disease 2019 (COVID-19).
    Tan A; Jones DM; Ahmad M
    Int J Cardiol; 2021 Mar; 327():259. PubMed ID: 33248186
    [No Abstract]   [Full Text] [Related]  

  • 64. [COVID-19 and Ophthalmology: A Never Ending Story?].
    Cursiefen C; Heiligenhaus A
    Klin Monbl Augenheilkd; 2021 May; 238(5):554. PubMed ID: 34020482
    [No Abstract]   [Full Text] [Related]  

  • 65. Letter to the Editor in response to the article: "Nebulization: a potential source of SARS-CoV-2 transmission".
    Anzueto A; Smyth HDC
    Respir Med Res; 2021 May; 79():100802. PubMed ID: 33618077
    [No Abstract]   [Full Text] [Related]  

  • 66. Re: "
    Rani R
    Assay Drug Dev Technol; 2021 Oct; 19(7):408-409. PubMed ID: 34463124
    [No Abstract]   [Full Text] [Related]  

  • 67. Letter to the Editor re: Baldassarri et al., 2021 "Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males".
    Ghanian S; Wambier CG
    EBioMedicine; 2021 Jun; 68():103425. PubMed ID: 34134086
    [No Abstract]   [Full Text] [Related]  

  • 68. Comment on: "The impact of COVID policies on acute ophthalmology services-experiences from Moorfields Eye Hospital NHS Foundation Trust".
    Schimansky S; Javed U; Mohamed Q
    Eye (Lond); 2021 Aug; 35(8):2329-2330. PubMed ID: 32827000
    [No Abstract]   [Full Text] [Related]  

  • 69. Letter to the Editor From Viola et al: "Calcifediol Treatment and COVID-19-related Outcomes".
    Viola V; Leanza G; Tramontana F
    J Clin Endocrinol Metab; 2021 Nov; 106(12):e5271-e5272. PubMed ID: 34383045
    [No Abstract]   [Full Text] [Related]  

  • 70. Response to Letter to the Editor From Viola et al: "Calcifediol Treatment and COVID-19-related Outcomes".
    Nogues X; Quesada-Gomez JM; Garcia-Giralt N
    J Clin Endocrinol Metab; 2021 Nov; 106(12):e5281-e5282. PubMed ID: 34331760
    [No Abstract]   [Full Text] [Related]  

  • 71. In response to the letter to the editor by Soha Ghanian et al. re our publication "Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males".
    Isidori AM; Marcelli M; Castagna MG; Baldassarri M; Fava F; Renieri A
    EBioMedicine; 2021 Jun; 68():103426. PubMed ID: 34134089
    [No Abstract]   [Full Text] [Related]  

  • 72. Letter to editor: Alimentary system is directly attacked by SARS-COV-2 and further prevents immune dysregulation caused by COVID-19.
    Rao K
    Int J Clin Pract; 2021 Aug; 75(8):e14049. PubMed ID: 34289645
    [No Abstract]   [Full Text] [Related]  

  • 73. COVID-19 letter to the editor: Epicardial fat inflammation as possible enhancer in COVID-19?
    Zhao Y; Chen M; Yang X; Zhao L
    Metabolism; 2021 Apr; 117():154722. PubMed ID: 33548252
    [No Abstract]   [Full Text] [Related]  

  • 74. Response to Letter to the Editor: Does Coronavirus Disease 2019 Infection Affect Dental Implant Integration?
    Block MS
    J Oral Maxillofac Surg; 2021 Jun; 79(6):1185-1186. PubMed ID: 33753050
    [No Abstract]   [Full Text] [Related]  

  • 75. Letter to the editor: Excess all-cause mortality during second wave of COVID-19 - the Polish perspective.
    Grabowski J; Witkowska N; Bidzan L
    Euro Surveill; 2021 Feb; 26(7):. PubMed ID: 33602384
    [No Abstract]   [Full Text] [Related]  

  • 76. Letter to the Editor in regard to the "Effects of COVID-19 on in-hospital cardiac arrest: incidence, causes, and outcome" by Roedl et al.".
    Krieg AD; Duval-Arnould J; Newton H; Winters BD; Hunt EA
    Scand J Trauma Resusc Emerg Med; 2021 Nov; 29(1):159. PubMed ID: 34732229
    [No Abstract]   [Full Text] [Related]  

  • 77. Letter to the Editor regarding "Long-term intubation and high rate of tracheostomy in COVID-19 patients might determine an unprecedented increase of airway stenoses: a call to action from the European Laryngological Society" by Piazza et al.
    Fiacchini G; Tricò D; Berrettini S; Bruschini L
    Eur Arch Otorhinolaryngol; 2021 May; 278(5):1709-1710. PubMed ID: 33569627
    [No Abstract]   [Full Text] [Related]  

  • 78. Letter to the editor: Keeping an eye on the many symptoms of COVID-19.
    Böcskei Z; Arnould L; Martel A; Bourcier T
    Graefes Arch Clin Exp Ophthalmol; 2021 Sep; 259(9):2861-2863. PubMed ID: 33704564
    [No Abstract]   [Full Text] [Related]  

  • 79. Letter by Vazgiourakis et al Regarding Article, "Spectrum of Cardiac Manifestations in COVID-19: A Systematic Echocardiographic Study".
    Vazgiourakis V; Zakynthinos GE; Tsolaki V
    Circulation; 2021 Mar; 143(9):e749-e750. PubMed ID: 33646831
    [No Abstract]   [Full Text] [Related]  

  • 80. Letter by Carrizales-Sepúlveda et al Regarding Article, "Spectrum of Cardiac Manifestations in COVID-19: A Systematic Echocardiographic Study".
    Carrizales-Sepúlveda EF; Vera-Pineda R; Flores-Ramírez R
    Circulation; 2021 Mar; 143(9):e751-e752. PubMed ID: 33646833
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.